NCT04954989View on ClinicalTrials.gov

Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 6, 2024

Primary Completion Date

December 1, 2024

Study Completion Date

December 31, 2024

Conditions
Healthy
Interventions
BIOLOGICAL

Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU

Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of the experimental drug should be administered subcutaneously

BIOLOGICAL

Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU

Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) should be administered subcutaneously

Trial Locations (1)

Unknown

Azidus Laboratories, Chennai

All Listed Sponsors
lead

Megalabs

INDUSTRY

NCT04954989 - Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers | Biotech Hunter | Biotech Hunter